Hodgkin lymphoma (HL), is a B-cell lymphoma. HL is a common hematological malignancy, mostly seen in young and middle-aged people. According to NCCN guidelines, common treatment options include ABVD, BEACOPP, StandfordV, etc. Most HL have a good prognosis and even can be cured. However, some Refractory / Recurrent (R/R) HL, continue to progress during treatment or even relapse after the completion of a complete chemotherapy course 3 months. At this time, the best treatment for R/R HL is high-dose chemotherapy / Autologous Hematopoietic Stem Cell Transplantation (HDC/HSCT). This paper reports a case of Recurrence/Refractory (R/R) mediastinal Hodgkin's lymphoma that relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. After receiving a variety of treatments, including chemotherapy, radiotherapy, autologous hematopoietic stem cell transplantation and so on, no long-term sustained remission was achieved. Traditional chemotherapy regimen has not brought ideal therapeutic effect to patients, but the rapid development of immunotherapy in recent years has brought new hope to patients. Finally sustained remission was achieved under the treatment of Brentuximab Vedotin combined with PD-1 inhibitor. This paper combined with the literature reports and discussed the clinical characteristics, treatment process and related experience and thinking methods of immunotherapy related to PD-1 inhibitors in this refractory and easy-to-relapse case. To provide more clinical data for the application of immunotherapy in R/R HL.
| Published in | International Journal of Immunology (Volume 9, Issue 3) |
| DOI | 10.11648/j.iji.20210903.13 |
| Page(s) | 54-58 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2021. Published by Science Publishing Group |
Hodgkin Lymphoma, Refractory / Recurrent, Brentuximab Vedotin, PD-1 Inhibito, Immune
| [1] | Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW: US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016, 34: 2020-2027. 10.1200/jco.2015.63.1119. |
| [2] | Ansell SM: Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018, 93: 704-715. 10.1002/ajh.25071. |
| [3] | Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Bierman PJ, Boughan KM, Dabaja B, Gordon LI, Hernandez-Ilizaliturri FJ, Herrera AF, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, McKinney M, Metzger M, Morgan D, Mulroney C, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Winter JN, Yahalom J, Burns JL, Ogba N: Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. 2020, 18: 755. 10.6004/jnccn.2020.0026. |
| [4] | Stroh M, Winter H, Marchand M, Claret L, Eppler S, Ruppel J, Abidoye O, Teng SL, Lin WT, Dayog S, Bruno R, Jin J, Girish S: Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma. Clin Pharmacol Ther. 2017, 102: 305-312. 10.1002/cpt.587. |
| [5] | Lepik KV, Fedorova LV, Kondakova EV, Zalyalov YR, Babenko EV, Lepik EE, Kotselyabina PV, Beynarovich AV, Popova MO, Volkov NP, Stelmakh LV, Baykov VV, Moiseev IS, Mikhailova NB, Kulagin AD, Afanasyev BV: A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma. Hemasphere. 2020, 4: e480. 10.1097/HS9.0000000000000480. |
| [6] | Punnett A, Tsang RW, Hodgson DC: Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects. Seminars in radiation oncology. 2010, 20: 30-44. 10.1016/j.semradonc.2009.09.006. |
| [7] | Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF: cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003, 102: 1458-1465. 10.1182/blood-2003-01-0039. |
| [8] | Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco JA, Wahl AF, Meyer DL, Senter PD: Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003, 21: 778-784. 10.1038/nbt832. |
| [9] | Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012, 30: 2183-2189. 10.1200/jco.2011.38.0410. |
| [10] | Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X, Thomas SH, Forman SJ, Kane SE: CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin. Mol Cancer Ther. 2015, 14: 1376-1384. 10.1158/1535-7163.Mct-15-0036. |
| [11] | Chen R, Herrera AF, Hou J, Chen L, Wu J, Guo Y, Synold TW, Ngo VN, Puverel S, Mei M, Popplewell L, Yi S, Song JY, Tao S, Wu X, Chan WC, Forman SJ, Kwak LW, Rosen ST, Newman EM: Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma. Clin Cancer Res. 2020, 26: 1034-1044. 10.1158/1078-0432.Ccr-19-1768. |
| [12] | Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I, Vale RD: T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017, 355: 1428-1433. 10.1126/science.aaf1292. |
| [13] | Bröckelmann PJ, Goergen H, Keller U, Meissner J, Ordemann R, Halbsguth TV, Sasse S, Sökler M, Kerkhoff A, Mathas S, Hüttmann A, Bormann M, Zimmermann A, Mettler J, Fuchs M, von Tresckow B, Baues C, Rosenwald A, Klapper W, Kobe C, Borchmann P, Engert A: Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial. JAMA oncology. 2020, 6: 872-880. 10.1001/jamaoncol.2020.0750. |
| [14] | Negrin RS: Graft-versus-host disease versus graft-versus-leukemia. Hematology American Society of Hematology Education Program. 2015, 2015: 225-230. 10.1182/asheducation-2015.1.225. |
| [15] | Asakura S, Hashimoto D, Takashima S, Sugiyama H, Maeda Y, Akashi K, Tanimoto M, Teshima T: Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice. J Clin Invest. 2010, 120: 2370-2378. 10.1172/JCI39165. |
| [16] | Norde WJ, Maas F, Hobo W, Korman A, Quigley M, Kester MG, Hebeda K, Falkenburg JH, Schaap N, de Witte TM, van der Voort R, Dolstra H: PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. Cancer Res. 2011, 71: 5111-5122. 10.1158/0008-5472.CAN-11-0108. |
| [17] | Saha A, Aoyama K, Taylor PA, Koehn BH, Veenstra RG, Panoskaltsis-Mortari A, Munn DH, Murphy WJ, Azuma M, Yagita H, Fife BT, Sayegh MH, Najafian N, Socie G, Ahmed R, Freeman GJ, Sharpe AH, Blazar BR: Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood. 2013, 122: 3062-3073. 10.1182/blood-2013-05-500801. |
| [18] | Yoo SH, Keam B, Kim M, Kim SH, Kim YJ, Kim TM, Kim DW, Lee JS, Heo DS: Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. ESMO Open. 2018, 3: e000332. 10.1136/esmoopen-2018-000332. |
| [19] | Hwang YY, Khong PL, Kwong YL: Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma. Ann Hematol. 2017, 96: 1219-1220. 10.1007/s00277-017-3007-9. |
| [20] | Ramchandren R, Domingo-Domènech E, Rueda A, Trněný M, Feldman TA, Lee HJ, Provencio M, Sillaber C, Cohen JB, Savage KJ, WillenbacherR/R W, Ligon AH, Ouyang J, Redd R, Rodig SJ, Shipp MA, Sacchi M, Sumbul A, Armand P, Ansell SM: Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. J Clin Oncol. 2019, 37: 1997-2007. 10.1200/jco.19.00315. |
APA Style
Jiaxin Wang, Jiaxiong Tan, Yuhong Lu. (2021). A Case of Recurrence/Refractory Mediastinal Hodgkin's Lymphoma Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation: Immunotherapy Brings Hope. International Journal of Immunology, 9(3), 54-58. https://doi.org/10.11648/j.iji.20210903.13
ACS Style
Jiaxin Wang; Jiaxiong Tan; Yuhong Lu. A Case of Recurrence/Refractory Mediastinal Hodgkin's Lymphoma Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation: Immunotherapy Brings Hope. Int. J. Immunol. 2021, 9(3), 54-58. doi: 10.11648/j.iji.20210903.13
AMA Style
Jiaxin Wang, Jiaxiong Tan, Yuhong Lu. A Case of Recurrence/Refractory Mediastinal Hodgkin's Lymphoma Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation: Immunotherapy Brings Hope. Int J Immunol. 2021;9(3):54-58. doi: 10.11648/j.iji.20210903.13
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.iji.20210903.13,
author = {Jiaxin Wang and Jiaxiong Tan and Yuhong Lu},
title = {A Case of Recurrence/Refractory Mediastinal Hodgkin's Lymphoma Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation: Immunotherapy Brings Hope},
journal = {International Journal of Immunology},
volume = {9},
number = {3},
pages = {54-58},
doi = {10.11648/j.iji.20210903.13},
url = {https://doi.org/10.11648/j.iji.20210903.13},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.iji.20210903.13},
abstract = {Hodgkin lymphoma (HL), is a B-cell lymphoma. HL is a common hematological malignancy, mostly seen in young and middle-aged people. According to NCCN guidelines, common treatment options include ABVD, BEACOPP, StandfordV, etc. Most HL have a good prognosis and even can be cured. However, some Refractory / Recurrent (R/R) HL, continue to progress during treatment or even relapse after the completion of a complete chemotherapy course 3 months. At this time, the best treatment for R/R HL is high-dose chemotherapy / Autologous Hematopoietic Stem Cell Transplantation (HDC/HSCT). This paper reports a case of Recurrence/Refractory (R/R) mediastinal Hodgkin's lymphoma that relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. After receiving a variety of treatments, including chemotherapy, radiotherapy, autologous hematopoietic stem cell transplantation and so on, no long-term sustained remission was achieved. Traditional chemotherapy regimen has not brought ideal therapeutic effect to patients, but the rapid development of immunotherapy in recent years has brought new hope to patients. Finally sustained remission was achieved under the treatment of Brentuximab Vedotin combined with PD-1 inhibitor. This paper combined with the literature reports and discussed the clinical characteristics, treatment process and related experience and thinking methods of immunotherapy related to PD-1 inhibitors in this refractory and easy-to-relapse case. To provide more clinical data for the application of immunotherapy in R/R HL.},
year = {2021}
}
TY - JOUR T1 - A Case of Recurrence/Refractory Mediastinal Hodgkin's Lymphoma Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation: Immunotherapy Brings Hope AU - Jiaxin Wang AU - Jiaxiong Tan AU - Yuhong Lu Y1 - 2021/09/26 PY - 2021 N1 - https://doi.org/10.11648/j.iji.20210903.13 DO - 10.11648/j.iji.20210903.13 T2 - International Journal of Immunology JF - International Journal of Immunology JO - International Journal of Immunology SP - 54 EP - 58 PB - Science Publishing Group SN - 2329-1753 UR - https://doi.org/10.11648/j.iji.20210903.13 AB - Hodgkin lymphoma (HL), is a B-cell lymphoma. HL is a common hematological malignancy, mostly seen in young and middle-aged people. According to NCCN guidelines, common treatment options include ABVD, BEACOPP, StandfordV, etc. Most HL have a good prognosis and even can be cured. However, some Refractory / Recurrent (R/R) HL, continue to progress during treatment or even relapse after the completion of a complete chemotherapy course 3 months. At this time, the best treatment for R/R HL is high-dose chemotherapy / Autologous Hematopoietic Stem Cell Transplantation (HDC/HSCT). This paper reports a case of Recurrence/Refractory (R/R) mediastinal Hodgkin's lymphoma that relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. After receiving a variety of treatments, including chemotherapy, radiotherapy, autologous hematopoietic stem cell transplantation and so on, no long-term sustained remission was achieved. Traditional chemotherapy regimen has not brought ideal therapeutic effect to patients, but the rapid development of immunotherapy in recent years has brought new hope to patients. Finally sustained remission was achieved under the treatment of Brentuximab Vedotin combined with PD-1 inhibitor. This paper combined with the literature reports and discussed the clinical characteristics, treatment process and related experience and thinking methods of immunotherapy related to PD-1 inhibitors in this refractory and easy-to-relapse case. To provide more clinical data for the application of immunotherapy in R/R HL. VL - 9 IS - 3 ER -
Email: